Document Detail


Clinical trials in thrombolytic therapy: what do they tell us? INJECT 6-month outcomes data.
MedLine Citation:
PMID:  8990407     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Numerous controlled clinical trials have documented the efficacy of thrombolytic agents in reducing the risk of mortality after myocardial infarction (MI). As a result, it is no longer ethical to test a new thrombolytic regimen against placebo. Rather, promising new therapies must be compared with proven treatments. This has been the direction taken in trials of reteplase, a new recombinant plasminogen activator. Initial studies of double-bolus reteplase demonstrated its superior ability to produce. TIMI grade 2 or 3 flow at 90 minutes when compared with accelerated alteplase. A subsequent randomized, double-blind, 9-country study, the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial was designed to determine whether the efficacy of reteplase is at least equivalent to that of streptokinase. The 2 treatments were associated with similar frequencies of inhospital cardiac events, bleeding, and strokes. Likewise, no significant difference was apparent between the reteplase and streptokinase groups with regard to 35-day mortality (the primary endpoint), the combined endpoint of 35-day mortality plus continuing disability from inhospital stroke, or 6-month mortality. Unadjusted data from the 3 countries that contributed the majority of patients seemed to indicate a survival benefit, irrespective of treatment allocation, among patients who underwent interventional procedures. However, no such benefit was apparent when the data were adjusted for differences in the baseline characteristics of the patients enrolled in the different countries. Rather, intervention within the first 3 days post-MI was found to place patients at a substantially higher risk of 35-day mortality. Further insights into the relative efficacy of reteplase should emerge from the ongoing third Global Utilization of Strategies to Open Occluded Coronary Arteries (GUSTO-III) trial.
Authors:
R G Wilcox
Related Documents :
15548777 - Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke.
18788507 - Carotid endarterectomy with mini-invasive access in locoregional anaesthesia.
2204737 - Is routine duplex examination after carotid endarterectomy justified?
24915767 - Piggyback-acquired hypertrichosis.
19119087 - Defining the learning curve for video-assisted thyroidectomy.
11426167 - Radiofrequency medial branch neurotomy in litigant and nonlitigant patients with cervic...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Review    
Journal Detail:
Title:  The American journal of cardiology     Volume:  78     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1996 Dec 
Date Detail:
Created Date:  1997-02-06     Completed Date:  1997-02-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  20-3     Citation Subset:  AIM; IM    
Affiliation:
Queen's Medical Centre, University Hospital, Nottingham, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cerebrovascular Disorders / chemically induced
Coronary Circulation
Double-Blind Method
Fibrinolytic Agents / administration & dosage,  adverse effects,  therapeutic use*
Hemorrhage / chemically induced
Humans
Multicenter Studies as Topic
Myocardial Infarction / drug therapy
Placebos
Plasminogen Activators / administration & dosage,  adverse effects,  therapeutic use
Randomized Controlled Trials as Topic*
Recombinant Proteins / administration & dosage,  adverse effects,  therapeutic use
Streptokinase / administration & dosage,  adverse effects,  therapeutic use
Survival Rate
Thrombolytic Therapy*
Time Factors
Tissue Plasminogen Activator / administration & dosage,  adverse effects,  therapeutic use
Treatment Outcome
Vascular Patency
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Placebos; 0/Recombinant Proteins; 133652-38-7/reteplase; EC 3.4.-/Streptokinase; EC 3.4.21.-/Plasminogen Activators; EC 3.4.21.68/Tissue Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Patency trials with reteplase (r-PA): what do they tell us?
Next Document:  Prognostic markers in thrombolytic therapy: looking beyond mortality.